DSM-pharm execs 2012 top 50 pharma companies

Pharmaceutical Executive Magazine, 05/08/2012

This year’s PE50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals. The 50 this year sold $610 billion in human prescription pharmaceuticals, up just 2.8 percent from last year's $593 billion. The top 10 grew even more slowly—by just 2.6 percent—and accounted for 59 percent of the 50's total sales, just like last year.

Print Article Summary